Applicability of a reproducible flow cytometry scoring system in the diagnosis of refractory cytopenia of childhood Myelodysplastic syndrome (MDS) in childhood is rare and has an estimated incidence per year of about 0.8-1.8 per million children aged 0 to 14 years. [1] [2] [3] The most common subtype of childhood MDS, accounting for about half of all cases, is refractory cytopenia of childhood (RCC), defined as myelodysplasia without an increased blast count. 4, 5 Karyotype is normal in the majority of patients with RCC, and, in contrast to adults with MDS-refractory anemia, about 80% of children have a hypocellular bone marrow (BM). 6 Although morphologic criteria for diagnosing RCC are strictly defined, 5 differentiating RCC from the immune-mediated BM failure syndrome aplastic anemia can be challenging. Similarly, difficulties can be encountered in differentiating, based on morphologic criteria, non-clonal cytopenias from low-grade MDS in adults, especially in cases without cytogenetic aberrations or specific morphologic abnormalities such as ring sideroblasts. Flow cytometric immunophenotyping has been suggested as valuable addition to morphology in the diagnosis of MDS. 7 Recently, Ogata and others described a simple, reproducible flow cytometric scoring system as diagnostic tool in adult low-grade MDS with a sensitivity of 70% and a specificity of 93%. 8, 9 The diagnostic utility of this scoring system in RCC is unknown. Here we describe its applicability in childhood MDS, with emphasis on RCC, using pediatric advanced MDS patients, low-grade adult MDS patients, healthy individuals and cytopenic non-MDS patients as controls.
BM samples obtained from 82 primary RCC patients (median age: 10.5 years, range: 1.3-17.9), not previously treated with immunosuppressive therapy, were available for analysis by flow cytometry. Patients were diagnosed from June 2005-December 2011 and enrolled in the prospective, multi-center studies EWOG-MDS 2006 and EWOG-MDS RC06 (ClinicalTrial.gov: NCT00662090 and NCT00499070). BM was hypocellular in 66 patients (81%), and normo-or hypercellular in 16 of 82 patients (20%). Cytogenetic analysis was normal in 62 patients (76%), monosomy 7 was present in 5 patients (6%), and other aberrations in 5 patients (6%); in 10 of 82 patients (12%) no result was obtained due to insufficient metaphases. Institutional review boards of participating institutions approved the studies and parents or legal guardians of patients provided written informed consent for study participation. RCC was diagnosed according to WHO criteria 5 and confirmed by central review of BM morphology and histology. 10 BM samples were collected in heparinized tubes, sent to the Erasmus MC, and generally analyzed within 24 h from collection.
A minimum of 500 ml BM was lysed with NH 4 Cl, resuspended in 350 ml phosphate-buffered saline/bovine serum albumin or to a maximum concentration of 20 Â 10 6 cells/ml, and 50 ml aliquots were stained for 15 min at room temperature with CD7-FITC (3A1/1, 7F3, Sanquin, Amsterdam, the Netherlands), CD56-PE (C5.9, DAKO, Glostrup, Denmark), CD45-PerCP (2D1, BD Biosciences, Erembodegem, Belgium), CD19-PE-Cy7 (SJ25C1, BD), CD5-APC (L17F12, BD) and CD34ACP-Cy7 (8G12, BD) in tube 1, and CD3-FITC (SK7, BD), CD16-PE (B73.1, BD) and CD56-PE (C5.9 Zebra/ DAKO), CD45-PerCP (2D1, BD), CD10-PE-Cy7 (HI10a, BD), CD19-APC (SJ25C1, BD), and CD20-APC-Cy7 (L27, BD) or APC-H7 (L27, BD) in tube 2. Cells were acquired on a FACSCanto II flow cytometer (BD Biosciences). After exclusion of debris and dead cells based on scatter and CD45 expression, at least 100 000 cells were analyzed in 61 of 82 RCC patients (75%). In the remaining 21 patients, a median of 54 323 cells could be analyzed (range, 4 359-98 482). Flow cytometric data were analyzed with Infinicyt software (Cytognos, Salamanca, Spain) according to the published strategy. 9 Briefly, in tube 1, lymphocytes were gated within all nucleated cells in a CD45 and forward scatter (FSC) versus side scatter (SSC) plot, and blast cells were gated within CD45 versus CD34 and FSC versus SSC plots. Within this population, myeloid blast cells were identified as SSC high cells in a CD45 versus SSC plot (parameter 1), and B-cell progenitors were identified as SSC low cells (parameter 2). Next, the lymphocyte versus myeloid blast cell CD45 mean fluorescence intensity (MFI) ratio was calculated (parameter 3). In tube 2, lymphocytes and granulocytes were gated in CD45 and FSC versus SSC plots, and SSC peak channel values of granulocytes versus lymphocytes were calculated (parameter 4). Samples were evaluated based on the published cutoffs (determined in 281 adults with low-grade MDS and 257 non-clonal cytopenic adult controls): CD34 þ myeloid blast cells (parameter 1) X2%, CD34 þ B-cell progenitors within CD34 þ blast cells (parameter 2) p5%, lymphocyte/myeloid blast cell CD45 MFI ratio (parameter 3) p4 or X7.5, granulocyte/lymphocyte SSC peak channel ratio (parameter 4) p6. 9 Patients scored 1 point for each fulfilled criteria; patients scoring X2 points were considered likely to have MDS. 9 To validate the scoring system in our laboratory, 8 low-grade adult MDS patients, 28 cytopenic non-clonal adult controls, and 9 healthy adult controls were evaluated (Figure 1 ). Seven of 8 MDS patients (87.5%), 2 of 28 cytopenic controls (7.1%) and 0 of 9 healthy controls scored positive (X2 points) (Table 1) , which is comparable to the previously published sensitivity of 70% and specificity of 93%.
Subsequently, 82 RCC patients were analyzed (Figure 1 ). In these patients, the percentage of myeloid blast cells was generally Accepted article preview online 15 March 2013; advance online publication, 12 April 2013 not greater than 2%, the CD45 MFI of myeloid blast cells was in general not aberrant, the SSC of granulocytes was not decreased, and the percentage of CD34 þ B-cell progenitors was very heterogeneous, but in general not decreased. Importantly, in 35 patients, o500 CD34 þ blast cells and o25 CD34 þ B-cell progenitors (for evaluation of parameter 2), o50 CD34 þ myeloid blast cells (for evaluation of parameter 3), and/or o1000 granulocytes (for evaluation of parameter 4) were present for reliable analysis of all four parameters. Thus, of 82 patients, only 47 patients could be evaluated for all four parameters according to the previously published scoring system, 9 limiting its applicability to 57% of patients. Of those patients who could be evaluated completely, 4 of 47 patients (8.5%) scored X2 points (Table 1) , and were thus likely to have MDS according to the previously published criteria. 9 The patients who scored positive were slightly older than the total RCC cohort (median age at diagnosis: 13 versus 10.5 years); two patients carried a monosomy 7, and in two patients no cytogenetic result was obtained due to insufficient metaphases. Owing to the low sensitivity in the already limited number of patients that could be evaluated for all 4 parameters, the scoring system published by Ogata and others does not seem applicable in RCC.
To assess whether the scoring system, which is largely based on immunophenotyping of blast cells, might be applicable in pediatric advanced MDS, 10 cases with MDS-RAEB (refractory anemia with excess blasts) or RAEB-t were evaluated. Of these, eight (80%) scored positive.
To determine the specificity of the scoring system in a pediatric control population, 22 cytopenic non-clonal pediatric controls (3 Fanconi anemia, 1 transient erythroblastopenia of childhood, 1 idiopathic thrombocytopenia of childhood and 17 (very) severe aplastic anemia ((v)SAA) patients) were analyzed (Figure 1) . In 14 (all (v)SAA) of 22 cytopenic non-clonal pediatric controls, insufficient granulocytes and/or blast cells were present for evaluation of all parameters. Of the eight patients that could be evaluated completely, no patient scored X2 points (Table 1) . Parameters 1, 2 and 4 of the scoring system were also assessed in a historic control cohort of 23 healthy children (Table 1) . It appeared that the CD45 MFI ratio of lymphocytes and CD34
þ myeloid blast cells in Letters to the Editor the healthy pediatric controls was not comparable to the data obtained in other patients and controls. The former data were obtained using 4-color stainings, a different method (stain-lysewash) than the one employed in the other samples, and acquired on a FACSCalibur flow cytometer (BD Biosciences), which might explain the difference in CD45 ratio. Consequently, parameter 3 could not be used for the flow cytometric scoring system in our healthy pediatric controls. Out of 23 healthy children, 17 scored 0 points, 5 scored 1 point, and 1 scored 2 points when three of four parameters were analyzed. Theoretically, 6 of 23 healthy children (26%) could have scored 2 or more points had all four parameters been analyzed. It should be noted that the median percentages of CD34 þ myeloid blast cells and, particularly, CD34 þ B-cell progenitors in healthy children are higher than in healthy adults. Results are summarized in Figure 1 and Table 1 . Altogether, based on the analysis of 31 pediatric (23 healthy and 8 cytopenic) control samples, the theoretical specificity of the flow cytometric scoring system is at least 81% (25 of 31), which is comparable to the specificity obtained in adults. 9 In conclusion, the scoring system proposed by Ogata and others is not usefully applicable in RCC due to a limited number of patients that can be evaluated for all four parameters, and due to a low sensitivity in those patients that can be evaluated. Furthermore, given the differences in percentages of CD34 þ myeloid blast cells and CD34 þ B-cell progenitors between adults and children, different cutoff values for parameter 1 and 2 may be needed for evaluation of pediatric patients with advanced MDS. To evaluate whether other immunophenotypic abnormalities are present and might aid in diagnosing RCC, more detailed analyses of myeloid maturation patterns using novel software tools are currently underway. 11, 12 
